In this free webinar, learn how to develop multiplex, targeted proteomic assays to support preclinical and clinical studies. Attendees will gain insights into state-of-the-art proteomic analyses. The featured speaker will discuss application of proteogenomic approaches to identifying novel biomarkers. The speaker will summarize the growing incorporation of targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into preclinical research, clinical trials, clinical laboratories to support target discovery and more.
TORONTO, March 29, 2023 /PRNewswire-PRWeb/ -- Personalized oncology aims to match each patient to a specific therapy based on the molecular characteristics of their tumor. Currently, tumor DNA is sequenced, and genomics reports are given to physicians to help select targeted therapies for patients. While this genome-centric approach to precision oncology has extended the lives of subsets of patients, many patients do not respond to the selected therapy, and many whose tumors initially respond have a high chance of recurrence with resistant disease. New approaches are required to capture complex clinical phenotypes and better match patients to efficacious therapies.
Most molecularly targeted therapies (e.g., kinase inhibitors, immune checkpoint inhibitors) do not directly target the cancer genome but rather target proteins in cancer cells or the tumor microenvironment. Neither DNA nor RNA profiles are reliable indicators of protein expression or activity levels. Thus, directly quantifying the expression of target proteins and their networks throughout all phases of precision oncology, from drug development through to patient selection, is critically important.
This webinar will discuss the added value of proteogenomics to the current genome-driven approach to precision oncology. The speaker will summarize the growing incorporation of targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into: preclinical research; clinical trials and; clinical laboratories to support target discovery, pharmacodynamic and mechanism of action studies (e.g., PMID: 30385821, 34359745), correlative studies (e.g., PMID: 36259971) and the quantification of diagnostic proteins (e.g., PMID: 36388059). The establishment of proteomics represents an important component towards implementation of broader precision medicine efforts in oncology and beyond. (See also: PMID: 30487530 and PMID: 33798439.)
Register for this webinar to learn about the advantage of using proteomics to build next-gen diagnostic solutions for precision oncology.
Join Dr. Amanda Paulovich, MD, PhD, Professor and Aven Foundation Endowed Chair, Director, CLIA Targeted Proteomic Laboratory, Clinical Research Division, Fred Hutchinson Cancer Center, for the live webinar on Thursday, April 20, 2023, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Precision Oncology Approaches: Using Proteomics to Build Next-Gen Diagnostic Solutions.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article